A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials.

ABSTRACT: Gemtuzumab ozogamicin (GO) is an anti-CD33 monoclonal antibody linked to calicheamicin, a DNA damaging agent, and is a well-established therapeutic for treating acute myeloid leukemia (AML). In this study, we used LASSO regression modeling to develop a 10-gene DNA damage response gene expression score (CalDDR-GEx10) predictive of clinical outcome in pediatric AML patients treated with treatment regimen containing GO from the AAML03P1 and AAML0531 trials (ADE + GO arm, N = 301). When treated with ADE + GO, patients with a high CalDDR-GEx10 score had lower complete remission rates (62.8% vs. 85.5%, P = 1.7 7 * 10^-5) and worse event-free survival (28.7% vs. 56.5% P = 4.08 * 10^-8) compared to those with a low CalDDR-GEx10 score. However, the CalDDR-GEx10 score was not ass

SUBMITTER: Gbadamosi MO 

PROVIDER: S-EPMC9357169 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature